veltuzumab   Click here for help

GtoPdb Ligand ID: 8268

Synonyms: hA20 | IMMU-106
Immunopharmacology Ligand
Compound class: Antibody
Comment: Veltuzumab is a humanized monoclonal antibody targeting CD20. With the exeption of Asp101 in the complementarity-determining region 3 (CDR3) of the antibody's variable heavy chain, its CDRs are identical to rituximab [2]. This single amino acid substitution appears to account for veltuzumab's reduced off-rate compared to rituximab [2] as well as its enhanced capacity to induce antibody-dependent cellular cytotoxicity (ADCC), and complement-mediated cytotoxicity.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help
1. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. (2005)
The biology of CD20 and its potential as a target for mAb therapy.
Curr Dir Autoimmun, 8: 140-74. [PMID:15564720]
2. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. (2009)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Blood, 113 (5): 1062-70. [PMID:18941114]
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010)
CD20 deficiency in humans results in impaired T cell-independent antibody responses.
J Clin Invest, 120 (1): 214-22. [PMID:20038800]
4. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Clin Cancer Res, 10 (8): 2868-78. [PMID:15102696]